



<b>UTILITY PATENT APPLICATION TRANSMITTAL</b>  <small>(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))</small>		Attorney Docket No.		AFD641									
		First Inventor or Application Identifier		Jong-Beom Baek									
		Title	QUINOXALINE-CONTAINING AB2 MONOMER FOR HYPERBRANCHED AROMATIC POLY(ETHER-KETONES)										
		Express Mail Label No.											
<b>APPLICATION ELEMENTS</b> See MPEP chapter 600 concerning utility patent application contents				<b>ADDRESS TO:</b> Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450									
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>1. <input checked="" type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17)</p> <p>2. <input type="checkbox"/> Applicant claims small entity status (See 37 CFR 1.27)</p> <p>3. <input checked="" type="checkbox"/> Specification [ Total Pages <input type="text" value="10"/> ]  <small>(Preferred arrangement set forth below)</small>            - Descriptive title of the invention            - Cross Reference to Related Applications            - Statement Regarding Fed sponsored R&amp;D            - Reference to sequence listing, a table, or a computer program listing appendix            - Background of the Invention            - Brief Summary of the Invention            - Detailed Description            - Claim(s)            - Abstract of the Disclosure</p> <p>4. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [ Total Sheets <input type="text"/> ]</p> <p>5. Oath or Declaration [ Total Pages <input type="text" value="1"/> ]</p> <p style="margin-left: 20px;">a. <input checked="" type="checkbox"/> Newly executed (original or copy)</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d))  <small>(for continuation/divisional with Box 18 completed)</small></p> <p style="margin-left: 40px;">i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b>  <small>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</small></p> <p>6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</p> </div> <div style="width: 48%;"> <p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)</p> <p>8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> Computer Readable Form (CRF)</p> <p style="margin-left: 20px;">b. Specification Sequence Listing on:</p> <p style="margin-left: 40px;">i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or</p> <p style="margin-left: 40px;">ii. <input type="checkbox"/> Paper</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> Statements verifying identity of above copies</p> </div> </div>													
<b>ACCOMPANYING APPLICATION PARTS</b>													
<p>9. <input type="checkbox"/> Assignment Papers (cover sheet &amp; document(s))</p> <p>10. <input type="checkbox"/> 37 CFR 1.373(b) Statement <input checked="" type="checkbox"/> Power of Attorney</p> <p>11. <input type="checkbox"/> English Translation Document (if applicable)</p> <p>12. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS) PTO-1449 <input checked="" type="checkbox"/> Copies of IDS Citations</p> <p>13. <input type="checkbox"/> Preliminary Amendment</p> <p>14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(should be itemized)</small></p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s)</p> <p>16. <input checked="" type="checkbox"/> Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach for PTO/SB/35 or its equivalent.</p> <p>17. <input type="checkbox"/> Other: _____</p>													
<p>18. If a <b>CONTINUING APPLICATION</b>, check appropriate box, and supply the requisite information below and in a preliminary amendment:</p> <p style="margin-left: 20px;"> <input type="checkbox"/> Continuation    <input type="checkbox"/> Divisional    <input type="checkbox"/> Continuation in Part (CIP)    of prior application No: _____         </p> <p>Prior application information: Examiner: _____ Group / Art Unit: _____</p>													
<b>CORRESPONDENCE ADDRESS</b>													
<input checked="" type="checkbox"/> Customer Number or Bar Code Label		<b>000026902</b> <small>(Insert Customer No. or Attach bar code label here)</small>		or <input type="checkbox"/> Correspondence address below									
Name _____													
Address _____													
City _____		State _____		Zip Code _____									
Country _____		Telephone _____		Fax _____									
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;">Name (Print / Type)</td> <td style="width: 30%;">Charles E. Bricker</td> <td style="width: 20%;">Registration No. (Attorney / Agent)</td> <td style="width: 10%;">26,715</td> </tr> <tr> <td>Signature:</td> <td colspan="2" style="text-align: center;"> </td> <td>Date <u>10-16-2003</u></td> </tr> </table>						Name (Print / Type)	Charles E. Bricker	Registration No. (Attorney / Agent)	26,715	Signature:			Date <u>10-16-2003</u>
Name (Print / Type)	Charles E. Bricker	Registration No. (Attorney / Agent)	26,715										
Signature:			Date <u>10-16-2003</u>										

 19270 U.S. PTO  
 10/695730

102303

# FEE TRANSMITTAL for FY 2004

## Complete if Known

<b>Application Number</b>	60/453,333
<b>Filing Date</b>	02-28-2003
<b>First Named Inventor</b>	Jong-Beom Baek
<b>Group Art Unit</b>	
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	AFD641

**TOTAL AMOUNT OF PAYMENT** (\$) **770**
**METHOD OF PAYMENT** (check one)

**FEE CALCULATION** (continued)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number

**AF 01-0465**

Deposit Account Name

**Department of the Air Force**

- ☐ Charge Any Additional Fee Required under 37 CFR 1.16 and 1.17 ☐ Charge the Issue Fee set in 37 CFR 1.18 at the Mailing of the Notice of Allowance, 37 CFR 1.311(b)

2. ☐ Payment Enclosed:  
☐ Check ☐ Money Order ☐ Other

**FEE CALCULATION** (fees effective 10/01/2000)

**1. FILING FEE**

Lge Entity Fee Code	Lge Entity Fee (\$)	Sm. Entity Fee Code	Sm. Entity Fee (\$)	Fee Description	Fee Paid
1001	770	2001	385	Utility Filing Fee	770
1002	340	2002	170	Design Filing Fee	
1003	530	2003	265	Plant Filing Fee	
1004	770	2004	385	Reissue Filing Fee	
1005	160	2005	80	Provisional Filing Fee	
<b>SUBTOTAL (1)</b>					<b>(\$ 770)</b>

**2. CLAIMS**

	Extra	Fee from below	Fee Paid
Total Claims	1 - 20 = 0 X 18 = 0		
Independent claims	1 - 3 = 0 X 86 = 0		
Multiple dependent claims			0

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim
1204	86	2204	43	Reissue independent claims over original patent
1205	18	2205	9	Reissue claims in excess of 20 and over original patent

**SUBTOTAL (2)** (\$)

**3. ADDITIONAL FEES**

Large Entity Code	Large Entity Fee (\$)	Small Entity Code	Small Entity Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner Action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for response within first month	
1252	420	2252	210	Extension for response within second month	
1253	950	2253	475	Extension for response within third month	
1254	1480	2254	740	Extension for response within fourth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive unavoidably abandoned application	
1453	1330	2453	665	Petition to revive unintentionally abandoned application	
1501	1330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Statement	
8021	40	8021	40	Recording each patent assignment per property	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
Other fee (specify) _____					

**SUBTOTAL (3)** (\$)

\*Reduced by Basic Filing Fee Paid

Complete (if applicable)

<b>SUBMITTED BY</b>		<b>Registration. No.</b>		<b>Telephone</b>	
Typed or Printed Name		26,715		(937) 255-5052	
Signature		Date		10-16-2003	

<b>REQUEST AND CERTIFICATION UNDER 35 U.S.C. 122(b)(2)(B)(i)</b>	First Named Inventor	Jong-Beom Baek
	Title	QUINOXALINE-CONTAINING AB2 MONOMER FOR HYPERBRANCHED AROMATIC POLY(ETHER-KETONES)
	Atty Docket Number	AFD641

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 1.22(b).

10-16-2003  
Date

Charles E. Bricker  
Signature

Charles E. Bricker  
Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and be submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 US.C. 122(b)(2)(B)(iii)).**